| GR00053-A |
3633 |
NM_005540 |
INPP5B |
np |
sp |
none |
|
no |
|
Genome stability |
A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. |
Paulsen et al. |
2009 |
19647519 |
Cell line |
HeLa |
gamma-H2AX phosphorylation and DNA content |
Fluorescence |
siARRAY human genome siRNA library |
Genome-wide |
siRNA |
p-value |
Complex criteria |
Confidence groupings from 4 to 1 (highest level of confidence in group 4) |
GR00054-A |
3633 |
NM_005540 |
INPP5B |
np |
0.94 |
none |
|
no |
|
Combinatorial effect with paclitaxel |
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. |
Whitehurst et al. |
2007 |
17429401 |
Cell line |
NCI-H1155 |
Viability (synthetic lethal) |
ATP level |
# G-005000-01 |
Genome-wide |
siRNA |
Paclitaxel/control ratio |
Complex criteria |
Additional information about 87 high-confidence hits |
|
3633 |
3633 |
INPP5B |
np |
np |
Increased cell migration |
|
yes |
deconvoluted validated siRNAs: 2/4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00055-A-3 |
3633 |
3633 |
INPP5B |
np |
np |
Increased cell migration |
|
no |
|
Epithelial cell migration (3) |
Identification of genes that regulate epithelial cell migration using an siRNA screening approach. |
Simpson et al. |
2008 |
19160483 |
Cell line |
MCF-10A overexpressing ERBB2 |
Cell migration and viability |
Microscopy and fluorescence |
SMARTpool siRNA library and MAR library |
Selected genes |
siRNA |
Area score and Alamar score |
Complex criteria |
|
GR00056-A |
3633 |
NM_005540 |
INPP5B |
np |
0.932 |
none |
|
no |
|
Melanogenesis |
Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. |
Ganesan et al. |
2008 |
19057677 |
Cell line |
MNT-1 |
Melanin protein expression and viability |
Absorbance and luminescence |
rp |
Genome-wide |
siRNA |
Normalized absorbance ratio |
> 2 standard deviations below mean |
Additional information about a secondary screen (retest to determine false-positive rate) |
GR00057-A-1 |
3633 |
NM_005540 |
INPP5B |
M-021811-01 |
-0.21 |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (1) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Z-score |
> 4 |
Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00057-A-2 |
3633 |
NM_005540 |
INPP5B |
M-021811-01 |
sp |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (2) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Complex, SP |
Complex criteria |
Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00133-A-1 |
3633 |
3633 |
INPP5B |
np |
0.11024 |
none |
|
no |
|
Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) |
RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. |
Misselwitz et al. |
2011 |
21407211 |
Cell line |
HeLa |
Gentamycin protection invasion assay |
Fluorescence |
Druggable genome library V2.0 |
Druggable genes |
siRNA |
log2 median |
Complex criteria |
|
GR00149-A-1 |
3633 |
3633 |
INPP5B |
221267 |
93.6 |
Decreased cilium length after serum starvation |
|
yes |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
3633 |
3633 |
INPP5B |
221267 |
58.54 |
Decreased cilium length after serum starvation |
|
yes |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
3633 |
3633 |
INPP5B |
221269 |
32.55 |
Decreased cilium length after serum starvation |
|
yes |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
3633 |
3633 |
INPP5B |
221269 |
31.8 |
Decreased cilium length after serum starvation |
|
yes |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
3633 |
3633 |
INPP5B |
289549 |
91.4 |
Decreased cilium length after serum starvation |
|
yes |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00149-A-1 |
3633 |
3633 |
INPP5B |
289549 |
92.59 |
Decreased cilium length after serum starvation |
|
yes |
|
Ciliogenesis and cilium length (1) |
Functional genomic screen for modulators of ciliogenesis and cilium length. |
Kim et al. |
2010 |
20393563 |
Cell line |
htRPE |
Smoothed protein expression |
Fluorescence |
Human druggable genome siRNA library V3.1 |
Druggable genes |
siRNA |
Normalized percent inhibition |
> 1.5 OR < -1.5 standard deviations from mean |
|
GR00180-A-1 |
3633 |
3633 |
INPP5B |
PL-50011 |
0.909 |
none |
|
no |
|
Hepatitis C virus replication (1) |
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. |
Tai et al. |
2009 |
19286138 |
Cell line |
Huh7/Rep-Feo |
HCV replicon RNA copy number |
Luminescence |
siARRAY Human Genome siRNA Library |
Genome-wide |
siRNA |
q-value |
Complex criteria |
|
GR00184-A-1 |
3633 |
NM_005540 |
INPP5B |
M-021811-01 |
-1.79446509375745 |
none |
|
no |
|
Self-renewal and pluripotency in human embryonic stem cells (1) |
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. |
Chia et al. |
2010 |
20953172 |
Cell line |
hESC H1 |
POU5F1 protein expression |
Fluorescence |
SMARTpool siRNA library |
Genome-wide |
siRNA |
Z-score |
< -2 |
|
GR00197-A-1 |
3633 |
3633 |
INPP5B |
M-021811-01 |
1.103637293 |
none |
|
no |
|
Human papillomavirus oncogene expression regulation (1) |
Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. |
Smith et al. |
2010 |
20133580 |
Cell line |
C33A/BE2/18LCR c4 |
HPV18 LCR reporter activity |
Luminescence |
Human siGENOME SMARTpool library |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 |
GR00204-A-1 |
3633 |
NM_005540 |
INPP5B |
np |
6.21 |
none |
|
yes |
pooled siRNAs |
RTK/Ras pathway regulation (1) |
Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. |
Omerovic et al. |
2010 |
19922411 |
Cell line |
A549 |
Erk phosphorylation |
Fluorescence |
np |
Phosphatases |
siRNA |
Percentage |
Top 20 |
Additional information about a secondary screen (Panc-08-13 cells) |
GR00204-A-2 |
3633 |
NM_005540 |
INPP5B |
np |
42.153 |
none |
|
no |
pooled siRNAs |
RTK/Ras pathway regulation (2) |
Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. |
Omerovic et al. |
2010 |
19922411 |
Cell line |
A549 |
Akt phosphorylation |
Fluorescence |
np |
Phosphatases |
siRNA |
Percentage |
Top 20 |
Additional information about a secondary screen (Panc-08-13 cells) |
GR00205-A |
3633 |
3633 |
INPP5B |
SI00447783, SI02658579, SI02658586 |
np |
none |
|
no |
|
Mitotic exit regulation |
Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells. |
Schmitz et al. |
2010 |
20711181 |
Cell line |
HeLa |
H2B and IBB protein expression |
Fluorescence |
Human siRNA phosphatase V3.0 library |
Phosphatases |
siRNA |
Z-score |
> 3 |
Author-reviewed data. HeLa Kyoto strain |
GR00210-A |
3633 |
3633 |
INPP5B |
np |
sp |
Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, decreased cell spreading |
|
no |
clusters: MC2, DC-NE, CC8 |
Focal adhesion formation |
Multiparametric analysis of focal adhesion formation by RNAi-mediated gene knockdown. |
Winograd-Katz et al. |
2009 |
19667130 |
Cell line |
HeLa |
paxillin protein expression |
Fluorescence |
SMARTpool siARRAY siRNA Libraries |
Kinases, phosphatases and selected genes |
siRNA |
Z-score |
> 3.5 OR < -3.5 |
|
|
3633 |
NM_005540 |
INPP5B |
np |
1.10504 |
none |
|
no |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00236-A-1 |
3633 |
3633 |
INPP5B |
M-021811-01 |
1.14037951169498 |
none |
|
no |
|
Homologous recombination DNA double-strand break repair (HR-DSBR) (1) |
A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. |
Adamson et al. |
2012 |
22344029 |
Cell line |
DR-U2OS |
(HR-DSBR) DR-GFP reporter and DNA content |
Fluorescence |
Human siGENOME siRNA (G-005000-05) |
Genome-wide |
siRNA |
Relative HR ratio |
< ~0.4 OR > 1.88 |
Cutoff values correspond 2 standard deviations from the screen-wide mean |
GR00240-S-1 |
3633 |
NM_005540 |
INPP5B |
M-021811-01 |
-0.88 |
none |
|
yes |
|
TRAIL-induced apoptosis (1) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Z-score |
> 4 |
Author-submitted data |
GR00240-S-2 |
3633 |
NM_005540 |
INPP5B |
M-021811-01 |
1.49 |
none |
|
no |
Z-score 0.745 |
TRAIL-induced apoptosis (2) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability (synthetic lethal) |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Differential score |
> 3.6 AND viability Z-score < 4 |
Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. |
GR00242-A-1 |
3633 |
NM_005540 |
INPP5B |
np |
sp |
none |
|
no |
|
Selective autophagy regulation (1) |
Image-based genome-wide siRNA screen identifies selective autophagy factors. |
Orvedahl et al. |
2011 |
22020285 |
Cell line |
HeLa/GFP-LC3 |
Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression |
Fluorescence |
siGenome |
Genome-wide |
siRNA |
Z-score |
Complex criteria |
|
GR00249-S |
3633 |
3633 |
INPP5B |
J-021811-09 |
-1.37871 |
none |
|
no |
number of cells compared to control (%): 99.81 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
3633 |
3633 |
INPP5B |
M-021811-02 |
-0.72561 |
none |
|
no |
number of cells compared to control (%): 50.14 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
3633 |
3633 |
INPP5B |
s7456 |
-1.68939 |
Decreased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 97.09 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
3633 |
3633 |
INPP5B |
s7457 |
0.37003 |
none |
|
no |
number of cells compared to control (%): 87.93 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
3633 |
3633 |
INPP5B |
s7458 |
1.05919 |
Increased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 84.02 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00253-A |
3633 |
NM_005540 |
INPP5B |
np |
2.1735 |
Increased hepcidin::fluc mRNA expression |
|
|
|
hepcidin regulation |
Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. |
Mleczko-Sanecka et al. |
2014 |
24385536 |
Cell line |
Huh7 |
hepcidin::fluc mRNA expression |
Luminescence |
siGenome siARRAY SMARTpool |
Genome-wide |
siRNA |
Z-score |
> |
Cutoff < |
GR00255-A-1 |
3633 |
79993 |
ELOVL7 |
TRCN0000116227, TRCN0000116228, TRCN0000116229, TRCN0000116230, TRCN0000116231 |
-0.305652443 |
none |
|
|
|
Negative genetic interactions (1) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-1 |
3633 |
284001 |
CCDC57 |
TRCN0000122073, TRCN0000139012, TRCN0000139803, TRCN0000142976, TRCN0000145319 |
0.336016474 |
none |
|
|
|
Negative genetic interactions (1) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-1 |
3633 |
3633 |
INPP5B |
TRCN0000051673, TRCN0000051674, TRCN0000051675, TRCN0000051676, TRCN0000051677 |
1.52922369 |
none |
|
|
|
Negative genetic interactions (1) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-2 |
3633 |
3633 |
INPP5B |
TRCN0000051673, TRCN0000051674, TRCN0000051675, TRCN0000051676, TRCN0000051677 |
-0.443841568 |
none |
|
|
|
Negative genetic interactions (2) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-2 |
3633 |
79993 |
ELOVL7 |
TRCN0000116227, TRCN0000116228, TRCN0000116229, TRCN0000116230, TRCN0000116231 |
0.624752706 |
none |
|
|
|
Negative genetic interactions (2) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-2 |
3633 |
284001 |
CCDC57 |
TRCN0000122073, TRCN0000139012, TRCN0000139803, TRCN0000142976, TRCN0000145319 |
2.114120258 |
none |
|
|
|
Negative genetic interactions (2) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-3 |
3633 |
3633 |
INPP5B |
TRCN0000051673, TRCN0000051674, TRCN0000051675, TRCN0000051676, TRCN0000051677 |
0.016731808 |
none |
|
|
|
Negative genetic interactions (3) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-3 |
3633 |
79993 |
ELOVL7 |
TRCN0000116227, TRCN0000116228, TRCN0000116229, TRCN0000116230, TRCN0000116231 |
1.359872361 |
none |
|
|
|
Negative genetic interactions (3) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-3 |
3633 |
284001 |
CCDC57 |
TRCN0000122073, TRCN0000139012, TRCN0000139803, TRCN0000142976, TRCN0000145319 |
1.22114463 |
none |
|
|
|
Negative genetic interactions (3) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-4 |
3633 |
284001 |
CCDC57 |
TRCN0000122073, TRCN0000139012, TRCN0000139803, TRCN0000142976, TRCN0000145319 |
0.460893018 |
none |
|
|
|
Negative genetic interactions (4) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-4 |
3633 |
3633 |
INPP5B |
TRCN0000051673, TRCN0000051674, TRCN0000051675, TRCN0000051676, TRCN0000051677 |
-1.48305762 |
Negative genetic interaction between PTTG1-/- and PTTG1+/+ |
|
|
|
Negative genetic interactions (4) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-4 |
3633 |
79993 |
ELOVL7 |
TRCN0000116227, TRCN0000116228, TRCN0000116229, TRCN0000116230, TRCN0000116231 |
0.703052434 |
none |
|
|
|
Negative genetic interactions (4) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-5 |
3633 |
3633 |
INPP5B |
TRCN0000051673, TRCN0000051674, TRCN0000051675, TRCN0000051676, TRCN0000051677 |
0.196417366 |
none |
|
|
|
Negative genetic interactions (5) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -0.8 |
HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-5 |
3633 |
284001 |
CCDC57 |
TRCN0000122073, TRCN0000139012, TRCN0000139803, TRCN0000142976, TRCN0000145319 |
-0.196585166 |
none |
|
|
|
Negative genetic interactions (5) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -0.8 |
HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-5 |
3633 |
79993 |
ELOVL7 |
TRCN0000116227, TRCN0000116228, TRCN0000116229, TRCN0000116230, TRCN0000116231 |
0.244503065 |
none |
|
|
|
Negative genetic interactions (5) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -0.8 |
HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00297-A |
3633 |
|
INPP5B |
TRCN0000051673 |
-0.93 |
Decreased shRNA abundance |
|
|
|
Glucose limitation response |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
Birsoy et al. |
2014 |
24670634 |
Cell line |
Jurkat |
shRNA abundance in high and low glucose |
Deep sequencing |
TRC |
Selected genes |
shRNA |
Log2 ratio |
< -0.75 |
|
GR00297-A |
3633 |
|
INPP5B |
TRCN0000051676 |
0.31 |
none |
|
|
|
Glucose limitation response |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
Birsoy et al. |
2014 |
24670634 |
Cell line |
Jurkat |
shRNA abundance in high and low glucose |
Deep sequencing |
TRC |
Selected genes |
shRNA |
Log2 ratio |
< -0.75 |
|
GR00297-A |
3633 |
|
INPP5B |
TRCN0000051677 |
0.67 |
none |
|
|
|
Glucose limitation response |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
Birsoy et al. |
2014 |
24670634 |
Cell line |
Jurkat |
shRNA abundance in high and low glucose |
Deep sequencing |
TRC |
Selected genes |
shRNA |
Log2 ratio |
< -0.75 |
|
GR00297-A |
3633 |
|
ELOVL7 |
TRCN0000116227 |
0.06 |
none |
|
|
|
Glucose limitation response |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
Birsoy et al. |
2014 |
24670634 |
Cell line |
Jurkat |
shRNA abundance in high and low glucose |
Deep sequencing |
TRC |
Selected genes |
shRNA |
Log2 ratio |
< -0.75 |
|
GR00297-A |
3633 |
|
INPP5B |
TRCN0000051674 |
0.2 |
none |
|
|
|
Glucose limitation response |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
Birsoy et al. |
2014 |
24670634 |
Cell line |
Jurkat |
shRNA abundance in high and low glucose |
Deep sequencing |
TRC |
Selected genes |
shRNA |
Log2 ratio |
< -0.75 |
|
GR00297-A |
3633 |
|
INPP5B |
TRCN0000051675 |
0.34 |
none |
|
|
|
Glucose limitation response |
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides |
Birsoy et al. |
2014 |
24670634 |
Cell line |
Jurkat |
shRNA abundance in high and low glucose |
Deep sequencing |
TRC |
Selected genes |
shRNA |
Log2 ratio |
< -0.75 |
|
GR00300-A |
3633 |
|
INPP5B |
TRCN0000051673, TRCN0000051677, TRCN0000051676, TRCN0000051675, TRCN0000051674 |
0 |
none |
|
|
|
Combinatorial effect with RAF inhibitor PLX4720 |
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. |
Whittaker et al. |
2013 |
23288408 |
Cell line |
A375 |
shRNA abundance |
Sequencing |
TRC |
Genome-wide |
shRNA |
Number of shRNAs ranked Top1000 |
> 2 |
The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. |
GR00300-A |
3633 |
|
ELOVL7 |
TRCN0000116231, TRCN0000116230, TRCN0000116228, TRCN0000116227, TRCN0000116229 |
0 |
none |
|
|
|
Combinatorial effect with RAF inhibitor PLX4720 |
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. |
Whittaker et al. |
2013 |
23288408 |
Cell line |
A375 |
shRNA abundance |
Sequencing |
TRC |
Genome-wide |
shRNA |
Number of shRNAs ranked Top1000 |
> 2 |
The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. |
GR00300-A |
3633 |
|
CCDC57 |
TRCN0000139012, TRCN0000145319, TRCN0000142976, TRCN0000139803, TRCN0000122073 |
0 |
none |
|
|
|
Combinatorial effect with RAF inhibitor PLX4720 |
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. |
Whittaker et al. |
2013 |
23288408 |
Cell line |
A375 |
shRNA abundance |
Sequencing |
TRC |
Genome-wide |
shRNA |
Number of shRNAs ranked Top1000 |
> 2 |
The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. |
GR00303-A |
3633 |
NM_005540 |
INPP5B |
np |
0.38 |
none |
|
|
|
Clear cell renal cell carcinoma (ccRCC) survival regulation |
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target |
Gerlinger et al. |
2012 |
22362593 |
Cell line |
VHL-deficient RCC4 |
Proliferation and Viability |
Fluorescence |
np |
Genome-wide |
siRNA |
Z-score |
< |
In the phenotype data duplicates were in the original document, which have been removed. |
GR00310-A-1 |
3633 |
3633 |
INPP5B |
np |
-0.35 |
none |
|
|
|
Sindbis virus (SINV) infection (1) |
Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry |
Ooi et al. |
2013 |
24367265 |
Cell line |
U2OS |
Sindbis virus (SINV) reporter |
Luminescence |
Ambion Silencer V3 |
Genome-wide |
siRNA |
Z-score |
< -3 OR > 2 |
|
|
3633 |
3633 |
INPP5B |
np |
15.2 |
none |
|
|
101,1% viability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00313-A |
3633 |
NM_005540 |
INPP5B |
np |
-0.4 |
none |
|
|
|
TNF-alpha pathway regulation |
A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. |
Nickles et al. |
2012 |
22733992 |
Cell line |
HEK293T |
NFkappaB pathway reporter |
Luminescence |
Qiagen |
Genome-wide |
siRNA |
Z-score |
< |
Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. |
GR00318-A |
3633 |
3633 |
INPP5B |
np |
1.337 |
none |
|
|
siRNA set: druggable genome |
Huntingtin toxicity |
A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease |
Miller et al. |
2012 |
23209424 |
Cell line |
HEK293T |
Caspase 3/7 activity |
Fluorescence |
Dharmacon |
Selected genes |
siRNA |
Sum of normalized caspase 3/7 activity mean and standard error |
< 0.683 |
HEK293T cells were cotransfected with mutant Huntingtin fused to GFP (Htt1-558141Q-GFP). |
GR00327-A |
3633 |
3633 |
GOPC |
CLL-H-011704 |
-0.752531844722704 |
none |
|
|
|
Tumor formation |
An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation |
Wolf et al. |
2013 |
24292671 |
Cell line |
SUM-149 |
shRNA abundance |
Next-generation sequencing |
Decipher library module 1 |
Selected genes |
shRNA |
Z-score |
> 2.24 |
Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. |
GR00327-A |
3633 |
3633 |
GOPC |
CLL-H-011703 |
1.7056321538064423 |
none |
|
|
|
Tumor formation |
An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation |
Wolf et al. |
2013 |
24292671 |
Cell line |
SUM-149 |
shRNA abundance |
Next-generation sequencing |
Decipher library module 1 |
Selected genes |
shRNA |
Z-score |
> 2.24 |
Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. |
GR00327-A |
3633 |
3633 |
GOPC |
CLL-H-011701 |
1.0021964354923187 |
none |
|
|
|
Tumor formation |
An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation |
Wolf et al. |
2013 |
24292671 |
Cell line |
SUM-149 |
shRNA abundance |
Next-generation sequencing |
Decipher library module 1 |
Selected genes |
shRNA |
Z-score |
> 2.24 |
Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. |
GR00327-A |
3633 |
3633 |
GOPC |
CLL-H-011700 |
0.5203068365527728 |
none |
|
|
|
Tumor formation |
An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation |
Wolf et al. |
2013 |
24292671 |
Cell line |
SUM-149 |
shRNA abundance |
Next-generation sequencing |
Decipher library module 1 |
Selected genes |
shRNA |
Z-score |
> 2.24 |
Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. |
GR00327-A |
3633 |
3633 |
GOPC |
CLL-H-011702 |
-0.013492860465052733 |
none |
|
|
|
Tumor formation |
An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation |
Wolf et al. |
2013 |
24292671 |
Cell line |
SUM-149 |
shRNA abundance |
Next-generation sequencing |
Decipher library module 1 |
Selected genes |
shRNA |
Z-score |
> 2.24 |
Genes were scored as hit if at least 2 shRNAs scored as hit, see comment. |
GR00343-S |
3633 |
3633 |
INPP5B |
TRCN0000051676 |
0.8500000000000014 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
3633 |
3633 |
INPP5B |
TRCN0000051677 |
0.6474999999999991 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
3633 |
3633 |
INPP5B |
TRCN0000051673 |
-1.049999999999999 |
shRNA abundance <= 50% |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
3633 |
3633 |
INPP5B |
TRCN0000051674 |
-0.5275000000000016 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
3633 |
3633 |
INPP5B |
TRCN0000051675 |
0.3525000000000009 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00350-A |
3633 |
3633 |
INPP5B |
np |
np |
Decreased HPV16-GFP infection |
|
|
not confirmed in secondary screen |
Human papilloma virus (HPV) infection |
Large Scale RNAi Reveals the Requirement of Nuclear Envelope Breakdown for Nuclear Import of Human Papillomaviruses |
Aydin et al. |
2014 |
24874089 |
Cell line |
HeLa |
HPV16-GFP infection |
Fluorescence |
Qiagen Druggable Genome Library |
Druggable genes |
siRNA |
Average z-score of 3 siRNAs |
< -3 OR > 3 |
See comments for validation screen results. The full set of images and analysis results is available at http://www.infectome.org. |
GR00363-A |
3633 |
3633 |
INPP5B |
289549, SI00447790, 221267, 221268, 221269, SI02658586, SI02658579, SI00447783, 292453, 292452 |
sp |
Decreased epidermal growth factor (EGF) endocytosis, decreased transferrin (TF) endocytosis |
|
|
weak but specific |
Endocytosis regulation |
Systems survey of endocytosis by multiparametric image analysis. |
Collinet et al. |
2010 |
20190736 |
Cell line |
HeLa |
Transferrin (TF) and epidermal growth factor (EGF) subcellular localisation, DNA content |
Fluorescence |
Ambion, Qiagen and esiRNA library (Kittler et al.) |
Genome-wide |
siRNA |
Complex, sp |
Complex criteria |
Two hit categories: "strong" (maximum of Prob Chi2, Prob Chi2 EGF, Prob Chi2 Tfn > 0.95) and "weak but specific" (maximum of Prob Chi2, Prob Chi2 EGF, Prob Chi2 Tfn < 0.95 but Phenoscore > 0.95). Additional information about secondary screens with kinase and phospatase libraries. |
|
3633 |
3633 |
INPP5B |
|
0.13 |
none |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00371-A-1 |
3633 |
3633 |
INPP5B |
|
-0.262673705663 |
none |
|
|
Dharmacon |
Nanog expression in absence of bFGF and TGFbeta |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-3 |
3633 |
3633 |
INPP5B |
|
-0.26051311014 |
none |
|
|
Dharmacon |
Nanog expression in presence of MEK inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-4 |
3633 |
3633 |
INPP5B |
|
-0.756980161424 |
none |
|
|
Dharmacon |
Nanog expression in presence of PI3K inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-5 |
3633 |
3633 |
INPP5B |
|
-0.771770487729 |
none |
|
|
Dharmacon |
Nanog expression in presence of retinoic acid |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00376-A-1 |
3633 |
3633 |
INPP5B |
|
0.48705905 |
none |
|
|
|
Mitigators of SS1P-induced immunotoxicity |
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity |
Pasetto et al. |
2015 |
25713356 |
Cell line |
KB cells |
Viability |
Luminescence |
Ambion Silencer Select Version 4 |
Genome-wide |
siRNA |
RSA P-value |
<0.001 |
SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID |
GR00376-A-2 |
3633 |
3633 |
INPP5B |
|
0.088955467 |
none |
|
|
|
Sensitizers of SS1P-induced immunotoxicity |
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity |
Pasetto et al. |
2015 |
25713356 |
Cell line |
KB cells |
Viability |
Luminescence |
Ambion Silencer Select Version 4 |
Genome-wide |
siRNA |
RSA P-value |
<0.001 |
SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID |
|
3633 |
NM_005540 |
INPP5B |
|
27.014 |
none |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00386-A-1 |
3633 |
3633 |
INPP5B |
|
102.86308910582 |
none |
|
|
|
NOD2 stimulation by MDP |
A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. |
Warner et al. |
2014 |
25170077 |
Cell line |
HEK293 stably expressing NOD2 |
Viability |
Luminescence |
Dharmacon |
Genome-wide |
siRNA |
Percentage growth |
Decreased: <70, increased: >120 |
Reagent IDs not provided |
GR00386-A-2 |
3633 |
3633 |
INPP5B |
|
-330.5 |
Increased IL-8 secretion |
|
|
|
MDP-induced IL-8 secretion |
A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. |
Warner et al. |
2014 |
25170077 |
Cell line |
HEK293 stably expressing NOD2 |
IL-8 secretion |
ELISA |
Dharmacon |
Genome-wide |
siRNA |
Percent inhibition of IL-8 secretion |
Increased: <-300, Decreased: >60 |
Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |